UBS Group Has Lowered Expectations for Kenvue (NYSE:KVUE) Stock Price

Kenvue (NYSE:KVUE) had its target price decreased by equities research analysts at UBS Group from $24.00 to $23.00 in a report issued on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. UBS Group’s target price points to a potential upside of 8.98% from the stock’s current price.

A number of other equities research analysts have also issued reports on the company. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $21.00 to $26.00 in a research report on Monday, January 6th. JPMorgan Chase & Co. boosted their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Barclays raised shares of Kenvue to a “hold” rating in a report on Thursday, December 12th. Finally, Citigroup cut their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $23.08.

Kenvue Stock Down 0.4 %

KVUE opened at $21.11 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The firm has a 50 day moving average price of $22.42 and a 200 day moving average price of $21.66. The company has a market cap of $40.46 billion, a PE ratio of 38.37, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same quarter in the previous year, the business posted $0.31 EPS. The business’s quarterly revenue was down .4% on a year-over-year basis. Sell-side analysts expect that Kenvue will post 1.14 earnings per share for the current year.

Hedge Funds Weigh In On Kenvue

A number of hedge funds have recently bought and sold shares of KVUE. Huntington National Bank lifted its holdings in Kenvue by 26.5% during the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company’s stock worth $96,000 after buying an additional 871 shares during the last quarter. ING Groep NV raised its position in shares of Kenvue by 23.6% during the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock valued at $82,727,000 after acquiring an additional 681,954 shares in the last quarter. Saturna Capital Corp lifted its stake in Kenvue by 29.9% during the third quarter. Saturna Capital Corp now owns 1,334,860 shares of the company’s stock worth $30,875,000 after purchasing an additional 307,039 shares during the last quarter. Everence Capital Management Inc. boosted its holdings in Kenvue by 122.1% in the fourth quarter. Everence Capital Management Inc. now owns 45,380 shares of the company’s stock worth $969,000 after purchasing an additional 24,950 shares during the period. Finally, Tyler Stone Wealth Management increased its stake in Kenvue by 134.4% during the third quarter. Tyler Stone Wealth Management now owns 49,050 shares of the company’s stock valued at $1,135,000 after purchasing an additional 28,125 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.